AstraZeneca/£AZN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Primary listing
LSE
Employees
94,300
Headquarters
Website
AstraZeneca Metrics
BasicAdvanced
£177B
29.17
£3.90
0.15
£2.45
2.15%
Price and volume
Market cap
£177B
Beta
0.15
52-week high
£122.56
52-week low
£95.74
Average daily volume
2.1M
Dividend rate
£2.45
Financial strength
Current ratio
0.863
Quick ratio
0.664
Long term debt to equity
57.992
Total debt to equity
73.508
Dividend payout ratio (TTM)
59.51%
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
14,058.889
Gross margin (TTM)
82.26%
Net profit margin (TTM)
14.68%
Operating margin (TTM)
25.40%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
£440,990
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
19.67%
Valuation
Price to earnings (TTM)
29.167
Price to revenue (TTM)
4.249
Price to book
3.95
Price to tangible book (TTM)
-12.24
Price to free cash flow (TTM)
28.83
Free cash flow yield (TTM)
3.47%
Free cash flow per share (TTM)
3.947
Dividend yield (TTM)
2.15%
Growth
Revenue change (TTM)
15.00%
Earnings per share change (TTM)
28.86%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.20%
3-year earnings per share growth (CAGR)
86.70%
10-year earnings per share growth (CAGR)
18.97%
3-year dividend per share growth (CAGR)
2.58%
10-year dividend per share growth (CAGR)
1.12%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca delivered second-quarter 2025 revenue growth of 11% year-over-year to $14.46 billion, with core EPS of $2.17 beating analyst expectations and confirming strong earnings momentum. (Reuters)
AstraZeneca’s experimental hypertension drug baxdrostat met both primary and secondary endpoints in a late-stage trial, significantly reducing systolic blood pressure and setting up for a potential regulatory submission by year-end, with projected peak sales exceeding $5 billion. (Reuters)
AstraZeneca has announced the acquisition of cell therapy specialist EsoBiotec for up to $1 billion, strengthening its in vivo immune cell engineering expertise and expanding its oncology and autoimmune portfolio, without altering its 2025 financial guidance. (Reuters)
AstraZeneca faces ongoing pricing pressure in the U.S. and could be hit by pharmaceutical tariffs due to global trade tensions, potentially squeezing profit margins even as sales rise. (Reuters)
AstraZeneca’s experimental therapy anselamimab did not achieve the primary endpoint in a Phase III trial for AL amyloidosis, highlighting serious risk in its rare diseases pipeline. (Reuters)
AstraZeneca could face up to $8 million in import tax fines in China as investigations continue over unpaid taxes on its cancer drugs, a revenue risk in a market representing about 12% of global sales. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £177B as of September 18, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 29.17 as of September 18, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is £2.447 and the yield is 2.15%. AstraZeneca has a payout ratio of 59.51% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.